|
|||||
|
|
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. |
|
| Authors: | Christopher G Willett Yves Boucher Dan G Duda Emmanuelle di Tomaso Lance L Munn Ricky T Tong Sergey V Kozin Lucine Petit Rakesh K Jain Daniel C Chung Dushyant V Sahani Sanjeeva P Kalva Kenneth S Cohen David T Scadden Alan J Fischman Jeffrey W Clark David P Ryan Andrew X Zhu Lawrence S Blaszkowsky Paul C Shellito Mari Mino-Kenudson Gregory Y Lauwers |
| Abstract: | |
| Keywords: | |